In Vitro Evaluation of VIP/PACAP Receptors in Healthy and Diseased Human Tissues: Clinical Implications
- 1 December 2000
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 921 (1) , 1-25
Abstract
Abstract: The evaluation of peptide receptors in man is relevant to identifying the physiological target tissues of a given peptide and to selecting diseases with a sufficient receptor overexpression for diagnostic or therapeutic intervention. VIP/PACAP receptors have been evaluated in normal and diseased human non‐neuronal tissues by using in vitro receptor autoradiography with 125I‐VIP or 125I‐PACAP in tissue sections. As assessed by subtype‐selective VIP analogs, VIP receptors of the VPAC1 subtype are found in a wide variety of tissues including liver, breast, kidney, prostate, ureter, bladder, pancreatic ducts, gastrointestinal mucosa, lung, thyroid, adipose, and lymphoid tissues. VPAC2 receptors are predominantly found in vessels and smooth muscles, whereas PAC1 receptors are present in the adrenal medulla. VIP/PACAP receptors are expressed in the majority of the most frequently occurring human tumors, including breast, prostate, pancreas, lung, colon, stomach, liver, and bladder carcinomas, as well as lymphomas and meningiomas, predominantly as VPAC1 receptors, as do their tissues of origin. Although leiomyomas predominantly express VPAC2 receptors, glial tumors, pituitary adenomas, neuroblastomas, paragangliomas, pheochromocytomas, and endometrial carcinomas preferentially express PAC1 receptors. The very wide distribution of VIP/PACAP receptors in the normal human body is indicative of the key role of these peptides in human physiology and pathophysiology. Moreover, the receptor expression in tumors is the molecular basis for clinical applications of VIP/PACAP such as in vivo scintigraphy and radiotherapy of tumors as well as VIP/PACAP analog treatment for tumor growth inhibition.Keywords
This publication has 35 references indexed in Scilit:
- A Critical View of the Methods for Characterization of the VIP/PACAP Receptor SubclassesaAnnals of the New York Academy of Sciences, 1998
- Pituitary Adenylate-Cyclase-Activating Polypeptide (PACAP) Binding Sites and PACAP/Vasoactive Intestinal Polypeptide Receptor Expression in Human Pituitary AdenomasThe American Journal of Pathology, 1998
- The somatostatin receptor (SSTR) subtype 3 ACTS as an acceptor of vasocative intestinal peptide (VIP)Gastroenterology, 1998
- Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributionsEndocrinology, 1994
- Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumorsPeptides, 1994
- Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomasThe Journal of Clinical Endocrinology & Metabolism, 1993
- High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytesJournal of Neuroimmunology, 1990
- Absence of Immunoreactive Vasoactive Intestinal Polypeptide in Tissue from the Lungs of Patients with AsthmaNew England Journal of Medicine, 1989
- Vasoactive Intestinal Peptide Inhibits the Growth of Hamster Pancreatic Cancer But Not Human Pancreatic Cancer in VivoPancreas, 1988
- Modifications of VIP intestinal content associated with abnormal nervous myenteric plexus: A biologic feature of chronic intestinal obstructionThe Journal of Pediatrics, 1980